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Interventions to Increase Completion of Hepatitis B 
Vaccination in People who Inject Drugs: A Systematic 
Review and Meta-analysis
Stacy Tressler and Ruchi Bhandari
Department of Epidemiology, West Virginia University, Morgantown, West Virginia, USA
Increases in opioid misuse and injection drug use have resulted in a rise in acute cases of hepatitis B. We conducted a systematic review 
and meta-analysis of randomized studies to determine the effect (pooled odds ratio) of interventions to increase hepatitis B vaccination 
completion in people who inject drugs (PWID). Odds ratios from the included studies were combined to create a pooled odds ratio (OR) 
using the Inverse Heterogeneity Model. Eleven studies met the eligibility criterion of having a randomized intervention to increase hepatitis 
B virus vaccination completion among PWID. The odds of vaccine completion in the intervention group were greater than in the control/
comparison group (pooled OR, 2.53; 95% confidence interval [CI], 1.07–5.99). Subgroup analysis indicated that financial incentives were 
most effective (OR, 7.01; 95% CI, 2.88–17.06), followed by accelerated vaccine schedules (OR, 1.90; 95% CI, 1.14–3.14). Interventions using 
financial incentives and accelerated vaccine schedules are moderately effective at increasing hepatitis B vaccination completion in PWID.
Keywords.  hepatitis B; meta-analysis; people who inject drugs; vaccination.
Globally, ~90% of the world’s population lives in countries with 
a high or intermediate prevalence of hepatitis B [1]. Worldwide, 
~240 million people are chronically infected with hepatitis B 
virus (HBV), and in the Unites States, an estimated 2.2 million 
people are chronic carriers of the virus [2, 3]. It is estimated that 
chronic hepatitis B (CHB) infection is responsible for 50% of 
all cases of hepatocellular carcinoma, and 25% of people with 
CHB will die prematurely from complications of the disease [1].
Major risk factors for HBV infection in the United States in-
clude sexual exposure and injection drug use (IDU) [4]. Since 
2009, opioid misuse and IDU in the United States have resulted 
in an increase in acute cases of hepatitis B [2]. In 2015, 30.3% 
of newly HBV-infected people reported IDU as a risk factor 
[4]. Adults with compromised immune systems are more likely 
to develop chronic infection (20%) compared with those with 
a healthy immune system (5%) [1]. People who inject drugs 
(PWID) have a higher risk of developing chronic infection due 
to altered immune function and co-infections with hepatitis C 
virus (HCV) and HIV [5].
The rise in opioid misuse and IDU has highlighted the need 
to provide education and harm reduction services to PWID, in-
cluding HBV vaccination [2, 6]. Survey data from 2013 indicate 
that only one-third of adults have completed the 3-dose HBV 
vaccination series, and this number is estimated to be even lower 
in PWID [2]. PWID can be a difficult population to reach, and 
completion of the standard 3-dose series at 0, 1, and 6 months 
in this population can be challenging. For this reason, different 
strategies have been used to increase vaccination rates, including 
accelerated vaccine schedules, financial incentives, case manage-
ment, peer coaching, and motivational interviewing [7–17]. In 
2014, The World Health Organization (WHO) published guid-
ance on preventing HBV and HCV in PWID. Using a systematic 
review approach, the authors graded the quality of evidence for 
using an accelerated vaccine schedule, financial incentives, and 
peer-based strategies to improve health outcomes for people with 
substance use disorders [3]. Although the quality of the evidence 
supporting these strategies was low, the WHO recommends their 
use to prevent the transmission of HBV and HCV in PWID [3].
Objective
The primary objective of this study was to conduct a systematic 
review and meta-analysis of randomized controlled trials and 
randomized studies to determine the overall effect of strategies 
to increase HBV vaccination in PWID.
METHODS
Study Eligibility
The eligibility criteria for inclusion in this systematic review 
with meta-analysis were established a priori. Each study was 
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required to meet the following eligibility criteria: (1) ran-
domized controlled trial or randomized study with at least 1 
intervention group and 1 control/comparison group, (2) in-
tervention aimed at increasing adherence to completion of the 
HBV vaccine series as either a primary or secondary outcome, 
(3) outcome data available on completion of the 3-dose HBV 
vaccination series, and (4) a study sample that included PWID 
(representing either all or a percentage of the overall study 
sample). The gray literature was not searched, and only studies 
published in English were included.
Data Sources
An electronic search of PubMed, Web of Science, and Cochrane 
Library was performed on February 20, 2018. Search terms in-
cluded “inject*,” “drug use*,” “hepatitis B vacc*,” and “hepatitis 
B vaccine*.” MESH terms included “hepatitis B vaccines” and 
“substance abuse, intravenous.” There were no time restrictions 
placed on the search, and each database was searched from its 
inception through February 20, 2018. Hand-searching of refer-
ences was performed when reviewing relevant studies to iden-
tify randomized controlled trials (RCTs) not found during the 
electronic search. An additional search of the 3 databases was 
performed on June 19, 2019, to search for studies meeting the 
inclusion criteria that were published between February 20, 
2018, and June 19, 2019. No additional studies were identified.
Study Selection
Studies obtained from the search results were imported into 
EndNote (VXE; Thomas Reuters, New York, NY, USA). 
Duplicates were identified and removed. Titles and abstracts 
were reviewed to identify studies meeting the inclusion criteria. 
A flowchart detailing the exclusion process and the reasons for 
exclusion can be found in Figure 1. For studies using the same 
sample, the study with the data most relevant to the review topic 
was selected.
Data Extraction
Microsoft Excel (version 2010; Richmond, WA, USA) was used 
to develop a codebook for data extraction before article selec-
tion. Each study was coded on 51 items, including the following 
major categories of variables: (1) study characteristics, (2) in-
tervention characteristics, (3) participant characteristics, and 
(4) outcome characteristics. For studies with >1 intervention 
group, outcome data for the most intensive intervention were 
selected. If a true control group did not exist, the comparison 
group selected by the study authors was used. Data were in-
cluded in the meta-analysis even if studies reported outcome 
data for a PWID subpopulation.
Risk of Bias Assessment
Risk of bias was assessed for each included study using the 
Cochrane Risk of Bias tool [18]. Study bias was assessed as high, 
Records identified through database
searching
(n = 565)
Additional records identif ied through
other sources
(n = 3)




Full-text articles assessed for eligibility
(n = 60)





• Wrong study design (n =34)
• Wrong population (n = 1)
• Wrong outcome (n = 7)
• Same sample as another study (n = 6)
• Unable to retrieve full study (n = 1)
Records excluded
(n = 436)
• Not related to the review topic (n = 226)
• Wrong study design (n = 172)
• Wrong population (n = 23)
• Wrong outcome (n = 9)
• Systematic review or meta-analysis (n = 6)
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low, or unclear on the following measures: (1) random sequence 
generation, (2) allocation concealment, (3) blinding of partici-
pants and personnel, (4) blinding of outcome data, (5) incom-
plete outcome data, (6) selective reporting, and (7) other major 
sources of bias.
Statistical Analysis
All analyses were completed in Meta XL using the Inverse 
Heterogeneity Model (IVhet). Data on studies reporting ad-
justed and crude odds ratios (ORs) of completion of the 3-dose 
HBV vaccination series in the intervention group compared 
with the control/comparison group were entered into Meta XL. 
Adjusted and crude odds ratios were pooled to create an overall 
effect size. Pooled ORs with 95% confidence intervals (CIs) 
were calculated using the IVhet in Meta XL. Heterogeneity and 
inconsistency were assessed using the Q statistic (based on the 
chi-square test statistic) and I2. For the Q statistic, a P value <.10 
was indicative of statistically significant heterogeneity between 
studies. I2 scores of 25% (low), 50% (moderate), and 75% (high) 
were used to determine the amount of inconsistency between 
studies. Small-study effects were assessed using a funnel plot. 
Cumulative, influence, and subgroup analyses were conducted. 
Subgroup analyses included intervention type (accelerated, fi-
nancial, and case management or enhanced services) and re-
ported OR (adjusted vs crude).
RESULTS
Study Characteristics
A flowchart depicting the search strategy and study selection 
process can be found in Figure 1. A  total of 565 studies were 
identified through electronic database searches. An additional 
3 studies were identified through hand-searching references 
during review of full articles, for a total of 568 studies. Using 
both electronic and manual searching methods, 72 dupli-
cates were identified and removed. A total of 496 studies were 
screened for eligibility, resulting in the removal of 485 studies.
Eleven studies, representing 4027 participants, met the selec-
tion criteria and were included in the meta-analysis. All of the 
studies included adherence to the 3-dose HBV vaccine series as 
their primary outcome. Countries where the studies were con-
ducted included the United States (n = 7) Iran (n = 1), Denmark 
(n = 1), Australia (n = 1), and the United Kingdom (n = 1). 
Study settings included prison (n = 2), syringe exchange pro-
gram (n = 2), methadone maintenance program (n = 2), drug 
treatment program (n = 2), community (n = 1), streets in an 
urban area (n = 1), and a combination of shelters, drug treat-
ment facility, and streets (n = 1). An overview of study charac-
teristics can be found in Table 1.
Participant Characteristics
The mean age of participants ranged from 34 to 46.3  years. 
Studies had a greater proportion of males compared with 
females, with a range of 55% to 100% males. The studies varied 
on the percentage of participants who reported IDU and ranged 
from 8.9% to 100%. Five studies included only participants who 
reported IDU, and the other 6 studies included participants 
who reported IDU and other alcohol/drug use. Ten studies 
based IDU on self-report, and each study differed on whether 
the IDU was classified as current, recent, ever/lifetime, or fu-
ture risk. The only common variables reported for all 11 studies 
were percent IDU and percent males. Participant characteristics 
can be found in Table 1.
Intervention Characteristics
Interventions were classified into 3 main categories: (1) HBV 
vaccine schedule (n = 4), (2) monetary/financial incentives 
(n = 3), and (3) case management/enhanced services (n = 4). 
Four studies focused on schedule-based interventions using 
a variety of accelerated vaccine schedules for the intervention 
group and all controls/comparisons assigned to the standard 
schedule of 0, 1, and 6 months. Three studies used monetary 
or financial intervention, and incentives included cash and 
vouchers in both fixed and escalating amounts. Details of the 
amounts used in each study can be found in Table 1. The case 
management/enhanced services interventions included motiva-
tional interviewing, case management, coaching, and hepatitis 
care coordination. Study characteristics can be found in Table 1.
Risk of Bias Assessment
The Cochrane Risk of Bias assessment tool was used to rank 
the studies as having high, low, or unclear risk of bias on 7 do-
mains (Supplementary Figure 1). Due to the nature of the inter-
ventions, almost all studies were ranked as having a high risk 
of bias, based on 3 criteria: allocation concealment, blinding 
of participants and personnel, and blinding of outcome assess-
ment. For all studies, the risk of bias for selective outcome re-
porting was low. The risk of bias varied among studies for the 
other 3 criteria, namely random sequence generation, incom-
plete outcome data, and other issues.
Data Synthesis
Results of the OR for vaccine completion in the interven-
tion group compared with the control/comparison group can 
be found in Figure 2. An overall pooled OR of 2.53 (95% CI, 
1.07–5.99) indicated a statistically significant (P = .04) increase 
in the odds of completing the 3-dose vaccine in the interven-
tion groups compared with the control/comparison group. 
Study heterogeneity was statistically significant (P < .0001), 
and inconsistency was categorized as high (I2 = 89%). An in-
fluence analysis with each study excluded once revealed that 
results did not remain statistically significant when 4 of the 11 
studies were individually removed from the model once. The 
results of the influence analysis can be found in Supplementary 
Table 1. A  cumulative meta-analysis of the studies by year 
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have decreased since 2003 and have not remained statistically 
significant. Small-study bias was assessed using a funnel plot 
(Supplementary Figure 3), plotting the natural log OR for each 
study against its precision. Asymmetry in the funnel plot indi-
cated potential small-study effects or other sources of bias such 























Q = 94.53, P = .00,
I 2 = 89%












Figure 2. Forest plot of overall meta-analysis results using the Inverse Heterogeneity Model. Abbreviations: CI, confidence interval; IVhet OR, Inverse Heterogeneity Model 
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comparing results by type of intervention and type of OR were 
included in the analysis. Intervention types were categorized as 
vaccine schedule, monetary/financial incentives, and case man-
agement/enhanced services (Figure 3). For the vaccine schedule 
subgroup, the pooled OR was 1.90 (95% CI, 1.14–3.14), hetero-
geneity was not statistically significant (P = .13), and inconsist-
ency was moderate (I2 = 47%). The pooled OR for the monetary 
subgroup was 7.01 (95% CI, 2.88–17.06), heterogeneity was not 
statistically significant (P = .12), and inconsistency was mod-
erate (I2 = 53%). The case management/enhanced services sub-
group pooled OR was not statistically significant (OR, 2.92; 
95% CI, 0.54–15.66), heterogeneity was statistically significant 
(P < .0001), and inconsistency was high (I2 = 96%). Finally, the 
subgroup analysis of crude vs adjusted OR yielded the following 
results: the pooled OR for studies that reported adjusted ORs 
was 2.26 (95% CI, 1.02–4.97), heterogeneity was statistically 
significant (P < .0001), and inconsistency was high (I2 = 77%); 
the pooled OR for studies that reported crude ORs was 3.04 
(95% CI, 0.49–18.88), heterogeneity was statistically significant 
(P < .0001), and inconsistency was high (I2 = 94%) (Figure 4).
DISCUSSION
This systematic review and meta-analysis included 11 RCTs 
or randomized studies that implemented strategies to increase 
completion of the 3-dose HBV vaccine series in PWID. The 
pooled OR for all 11 studies indicated a statistically significant 
increase in the odds of completing all 3 doses in the interven-
tion group compared with the control/comparison group (OR, 
2.53; 95% CI, 1.07–5.99; P = .04). Subgroup analyses comparing 
the interventions by type indicated that the odds of vaccine 
completion in those who received financial incentives was the 
highest, followed by receipt of an accelerated vaccine schedule. 
Subgroup analysis of the case management/enhanced services 
group yielded an OR that was not statistically significant. These 
findings are consistent with WHO recommendations from 
2014 that were based on previous research to increase compli-
ance with HBV vaccination in PWID [3].
Hepatitis B is a vaccine-preventable disease that remains 
problematic in certain at-risk groups. Since 2009, the increase 
in IDU in the United States has highlighted the importance 
of providing harm-reduction services to PWID, including ac-
cess to HBV vaccine. However, making the vaccine available 
does not always translate to increased HBV vaccination rates 
in PWID. Strategies are needed to increase the vaccine uptake 
among this at-risk group. The cost of the vaccine is minimal 
compared with the savings from improved quality of life and 
reduced health care costs. In 1 study, the cost of providing fi-
nancial incentives to increase vaccine compliance was $220 per 
participant compared with the cost of increasing compliance 
through outreach methods, which equaled $590 per partic-
ipant [7]. Combining financial incentives with an accelerated 
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Figure 4. Forest plot of subgroup analysis by type of reported odds ratio using the Inverse Heterogeneity Model. Abbreviations: aOR, adjusted odds ratio; IVhet OR, Inverse 
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In 2017, the Food and Drug Administration approved 
Heplisav-B, a new 2-dose, highly immunogenic hepatitis B 
vaccine [19]. The new 2-dose series is administered at 0 and 
30 days, compared with the traditional series administered at 0, 
1, and 6 months. Use of the 2-dose series in future vaccine inter-
ventions among PWID may increase adherence and result in a 
higher immune response compared with the traditional 3-dose 
series. However, results from a recent study indicated that the 
percentage of at-risk people completing the second dose of the 
traditional HBV vaccine series  was only 40.4%, suggesting a 
need to incorporate strategies to increase HBV vaccine schedule 
adherence even for a 2-dose series [20].
More randomized controlled studies are needed to examine 
the effectiveness of interventions specifically in PWID. Based 
on findings from the Hu et al. (2008) study, administering the 
first dose of HBV in conjunction with testing for HBV is both 
cost-saving and effective and should be considered when con-
ducting future research [21]. Additionally, combining different 
strategies, for example, accelerated vaccine schedules with fi-
nancial incentives, may confound the association and make it 
difficult to determine the effectiveness of the individual inter-
vention. Therefore, future studies should compare only 1 inter-
vention strategy with 1 control group.
A potential limitation of this study was the significant amount 
of heterogeneity between the 11 studies. However, this limita-
tion was addressed through subgroup analysis of intervention 
type, which indicated that heterogeneity was not significant 
within  2 of the 3 subgroups. For this reason, the interpreta-
tion of the results from the intervention subgroup analysis may 
be more appropriate than the pooled OR. Additionally, the 11 
studies varied greatly on the percentage of people who reported 
IDU. Ten of the 11 studies relied on self-reported drug use and 
may have been influenced by bias. There was substantial varia-
tion in how and when people were randomized to the interven-
tion and control groups. All of the studies took place in either 
prison or urban areas, which may affect generalizability, espe-
cially to PWID living in rural areas. Generalizability to females 
may also be problematic due to the majority of participants 
being males. Some of the studies were part of larger studies, 
and data for the vaccine-eligible population were not always re-
ported. Publication bias and small-study effects may have influ-
enced the overall findings of the study, resulting in statistically 
significant results. Finally, coding studies proved problematic 
due to the quality of reporting. Several of the studies reported 
conflicting information in the text, charts, and tables, making it 
difficult to determine the true numbers.
CONCLUSIONS
Increasing HBV vaccination is a cost-effective way of preventing 
both primary and secondary infections in PWID. Using acceler-
ated vaccine schedules and financial incentives has been shown 
to increase compliance to the 3-dose vaccine schedule. As IDU 
continues, more research is needed to find strategies to improve 
health outcomes in this at-risk group.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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